Table 4 Association of clinicopathologic variables and circulating angiogenic cytokines with cancer-specific survival: univariate analyses
From: Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
| Â | n (%) | Cancer-specific survival n (%) | PValue* |
|---|---|---|---|
Total | 74 (100) | - | - |
Gender | Â | Â | 0.72 |
   Male | 37 (50.0) | 19 (51.3) |  |
   Female | 37 (50.0) | 14 (37.8) |  |
Age [years] | Â | Â | 0.22 |
   < 65 | 30 (40.5) | 14 (46.7) |  |
   ≥ 65 | 44 (59.5) | 19 (43.2) |  |
Location of the tumor | Â | Â | 0.74 |
   Pancreatic head | 54 (73.0) | 25 (46.3) |  |
   Pancreatic body | 14 (18.9) | 4 (28.6) |  |
   Pancreatic tail | 6 (8.1) | 4 (66.7) |  |
CA 19-9 level | Â | Â | 0.38 |
   < 37 [μg/l] | 20 (27.4) | 8 (40.0) |  |
   ≥ 37 [μg/l] | 53 (72.6) | 25 (47.2) |  |
CEA level | Â | Â | 0.59 |
   < 2.5 [μg/l] | 33 (45.2) | 14 (42.4) |  |
   ≥ 2.5 [μg/l] | 40 (54.8) | 19 (47.5) |  |
Lymph node status | Â | Â | 0.13 |
   N0 | 54 (73.0) | 26 (48.1) |  |
   N1 | 20 (27.0) | 7 (35.0) |  |
Tumor differentiation | Â | Â | 0.02 |
   Moderate (G2) | 48 (68.6) | 20 (41.7) |  |
   Poor (G3) | 22 (31.4) | 12 (54.5) |  |
Resection margin status | Â | Â | 0.08 |
   R0 | 27 (36.5) | 8 (29.6) |  |
   R1 | 47 (63.5) | 25 (53.2) |  |
VEGF | Â | Â | 0.19 |
   ≥ 32.1 | 37 (50.0) | 14 (37.8) |  |
   < 32.1 | 37 (50.0) | 19 (51.3) |  |
VEGFR-1 | Â | Â | 0.51 |
   ≥ 78.5 | 37 (50.0) | 15 (40.5) |  |
   < 78.5 | 37 (50.0) | 18 (48.6) |  |
PlGF | Â | Â | 0.84 |
   ≥ 11.4 | 37 (50.0) | 18 (48.6) |  |
   < 11.4 | 37 (50.0) | 15 (40.5) |  |
PDGF-AA | Â | Â | 0.53 |
   ≥ 2336.3 | 37 (50.0) | 19 (51.3) |  |
   < 2336.3 | 37 (50.0) | 14 (37.8) |  |
PDGF-BB | Â | Â | 0.10 |
   ≥ 7624.3 | 37 (50.0) | 13 (35.1) |  |
   < 7624.3 | 37 (50.0) | 20 (54.1) |  |
Ang-1 | Â | Â | 0.53 |
   ≥ 29202.1 | 37 (50.0) | 15 (40.5) |  |
   < 29202.1 | 37 (50.0) | 18 (48.7) |  |
EGF | Â | Â | 0.26 |
   ≥ 234.2 | 37 (50.0) | 17 (45.9) |  |
   < 234.2 | 37 (50.0) | 16 (43.2) |  |